Overview

IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC

Status:
Not yet recruiting

Trial end date:
2024-11-30

Target enrollment:

Participant gender:

Summary

A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of Head or Neck (SCCHN), orMetastatic Urothelial Bladder Cancer (mUBC)

Phase:

Phase 2

Details

Lead Sponsor:

IO Biotech

Collaborators:

Almac
NeoGenomics
Theradex

Treatments:

Pembrolizumab